专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015164308A1 FACTOR XIa INHIBITORS 审中-公开
标题翻译：因子XIA抑制剂
公开(公告)号：WO2015164308A1
公开(公告)日：2015-10-29
申请号：PCT/US2015/026774
申请日：2015-04-21
申请人： MERCK SHARP & DOHME CORP. , LIM, Yeon-Hee , GUO, Zhuyan , ALI, Amjad , EDMONDSON, Scott, D. , LIU, Weiguo , GALLO-ETIENNE, Gioconda, V. , WU, Heping , GAO, Ying-Duo , STAMFORD, Andrew, M. , YU, Younong , KEVIN, Nancy, J. , ANAND, Rajan , SHA, Deyou , NEELAMKAVIL, Santhosh, F. , HUSSAIN, Zahid , KUMAR, Puneet , MONINGKA, Remond , DUFFY, Joseph, L. , XU, Jiayi , JIANG, Yu , SONE, Hiroki , CHAKRABARTI, Anjan
发明人： LIM, Yeon-Hee , GUO, Zhuyan , ALI, Amjad , EDMONDSON, Scott, D. , LIU, Weiguo , GALLO-ETIENNE, Gioconda, V. , WU, Heping , GAO, Ying-Duo , STAMFORD, Andrew, M. , YU, Younong , KEVIN, Nancy, J. , ANAND, Rajan , SHA, Deyou , NEELAMKAVIL, Santhosh, F. , HUSSAIN, Zahid , KUMAR, Puneet , MONINGKA, Remond , DUFFY, Joseph, L. , XU, Jiayi , JIANG, Yu , SONE, Hiroki , CHAKRABARTI, Anjan
IPC分类号： C07D471/10 , A61K31/438 , C07D498/20
CPC分类号： C07D498/20 , C07D471/10 , C07D487/10 , C07D498/10 , C07F9/6561
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译：本发明提供式（I）的化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维变化的方法。该化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。

2. 发明申请

WO2015123091A1 FACTOR XIA INHIBITORS 审中-公开
标题翻译：因子XIA抑制剂
公开(公告)号：WO2015123091A1
公开(公告)日：2015-08-20
申请号：PCT/US2015/014708
申请日：2015-02-06
申请人： MERCK SHARP & DOHME CORP. , NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , GUO, Zhuyan , HRUZA, Alan, W. , HUSSAIN, Zahid , MONINGKA, Remond , KEVIN, Nancy Jo
发明人： NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , GUO, Zhuyan , HRUZA, Alan, W. , HUSSAIN, Zahid , MONINGKA, Remond , KEVIN, Nancy Jo
IPC分类号： A01N37/12
CPC分类号： C07D217/24 , C07C55/32 , C07D209/46 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译：本发明提供式（I）的化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维变化的方法。该化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。

3. 发明申请

WO2015123090A1 FACTOR XIA INHIBITORS 审中-公开
标题翻译： FACTOR XIA抑制剂
公开(公告)号：WO2015123090A1
公开(公告)日：2015-08-20
申请号：PCT/US2015/014707
申请日：2015-02-06
申请人： MERCK SHARP & DOHME CORP. , NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , GUO, Zhuyan , HRUZA, Alan, W. , HUSSAIN, Zahid , LESBURG, Charles, A. , MONINGKA, Remond , OGAWA, Anthony, K. , MAL, Rudrajit
发明人： NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , GUO, Zhuyan , HRUZA, Alan, W. , HUSSAIN, Zahid , LESBURG, Charles, A. , MONINGKA, Remond , OGAWA, Anthony, K. , MAL, Rudrajit
IPC分类号： A01N37/12
CPC分类号： C07D487/08 , C07D471/08
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译：本发明提供式（I）化合物和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维化改变的方法。这些化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。

4. 发明申请

WO2015123093A1 FACTOR XIA INHIBITORS 审中-公开
公开(公告)号：WO2015123093A1
公开(公告)日：2015-08-20
申请号：PCT/US2015/014711
申请日：2015-02-06
申请人： MERCK SHARP & DOHME CORP. , NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , HRUZA, Alan, W. , HUSSAIN, Zahid , LESBURG, Charles , MONINGKA, Remond
发明人： NEELAMKAVIL, Santhosh, F. , EDMONDSON, Scott, D. , HRUZA, Alan, W. , HUSSAIN, Zahid , LESBURG, Charles , MONINGKA, Remond
IPC分类号： A01N37/12
CPC分类号： C07D471/08 , C07D487/08
摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

5. 发明申请

WO2011146324A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS 审中-公开
标题翻译： SPIRO ISOXAZOLINE化合物作为SSTR5拮抗剂
公开(公告)号：WO2011146324A1
公开(公告)日：2011-11-24
申请号：PCT/US2011/036367
申请日：2011-05-13
申请人： MERCK SHARP & DOHME CORP. , DUFFY, Joseph, L. , BAO, Jianming , ONDEYKA, Debra, L. , TYAGARAJAN, Sriram , SHAO, Patrick , YE, Feng , KATIPALLY, Revathi , FINKE, Paul, E. , ZANG, Yi , PLOTKIN, Michael, A. , ROMERO, F. Anthony , MONINGKA, Remond , HUSSAIN, Zahid
发明人： DUFFY, Joseph, L. , BAO, Jianming , ONDEYKA, Debra, L. , TYAGARAJAN, Sriram , SHAO, Patrick , YE, Feng , KATIPALLY, Revathi , FINKE, Paul, E. , ZANG, Yi , PLOTKIN, Michael, A. , ROMERO, F. Anthony , MONINGKA, Remond , HUSSAIN, Zahid
IPC分类号： A01N43/40 , A01N43/42 , A61K31/44
CPC分类号： C07D498/10 , C07D519/00
摘要： Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.
摘要翻译：结构式（I）的取代的螺环胺是生长抑素亚型受体5（SSTR5）的选择性拮抗剂，可用于治疗，控制或预防对SSTR5的拮抗作用有响应的病症，例如2型糖尿病，胰岛素抵抗，脂质障碍，肥胖症，动脉粥样硬化，代谢综合征，抑郁症和焦虑症。

6. 发明申请

WO2015047973A1 FACTOR XIa INHIBITORS 审中-公开
标题翻译：因子XIA抑制剂
公开(公告)号：WO2015047973A1
公开(公告)日：2015-04-02
申请号：PCT/US2014/056873
申请日：2014-09-23
申请人： MERCK SHARP & DOHME CORP. , MERTZ, Eric , EDMONDSON, Scott, D. , SHAO, Ning , NEELAMKAVIL, Santhosh , POKER, Corey , HUSSAIN, Zahid , GUO, Zhuyan , KEVIN, Nancy Jo , ZANG, Yi , HE, Jiafang
发明人： MERTZ, Eric , EDMONDSON, Scott, D. , SHAO, Ning , NEELAMKAVIL, Santhosh , POKER, Corey , HUSSAIN, Zahid , GUO, Zhuyan , KEVIN, Nancy Jo , ZANG, Yi , HE, Jiafang
IPC分类号： C07K14/745
CPC分类号： C07D401/14 , A01N1/0226 , C07D211/60 , C07D401/06 , C07D401/10 , C12N9/6443 , C12Y304/21027
摘要： The present invention provides a compound of Formula (I): and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
摘要翻译：本发明提供式（I）的化合物：和包含一种或多种所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓形成，栓塞，高凝状态或纤维变化的方法。该化合物是选择性因子XIa抑制剂或因子XIa和血浆激肽释放酶的双重抑制剂。

7. 发明申请

WO2018226771A1 PYRAZOLOPYRIMIDINE PDE9 INHIBITORS 审中-公开
公开(公告)号：WO2018226771A1
公开(公告)日：2018-12-13
申请号：PCT/US2018/036172
申请日：2018-06-06
申请人： MERCK SHARP & DOHME CORP. , ARASAPPAN, Ashok , COX, Jason, M. , DEBENHAM, John, S. , GUO, Zhuyan , HE, Jiafang , HUSSAIN, Zahid , LAI, Zhong , LI, Derun , MENG, Dongfang , RAGHAVAN, Subharekha , TYAGARAJAN, Sriram
发明人： ARASAPPAN, Ashok , COX, Jason, M. , DEBENHAM, John, S. , GUO, Zhuyan , HE, Jiafang , HUSSAIN, Zahid , LAI, Zhong , LI, Derun , MENG, Dongfang , RAGHAVAN, Subharekha , TYAGARAJAN, Sriram
IPC分类号： C07D487/04 , A61P25/00 , A61P9/00 , A61P25/18 , A61P13/12 , A61K31/519
摘要： The present invention is directed to pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

8. 发明申请

WO2021055728A8 SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT 审中-公开
公开(公告)号：WO2021055728A8
公开(公告)日：2021-03-25
申请号：PCT/US2020/051464
申请日：2020-09-18
申请人： MERCK SHARP & DOHME CORP. , HOOVER, Andrew, J. , GRAHAM, Thomas, H. , MA, Xiaoshen , HUSSAIN, Zahid , MANDAL, Mihir , GATHIAKA, Symon , HAN, Yongxin , SLOMAN, David, L.
发明人： HOOVER, Andrew, J. , GRAHAM, Thomas, H. , MA, Xiaoshen , HUSSAIN, Zahid , MANDAL, Mihir , GATHIAKA, Symon , HAN, Yongxin , SLOMAN, David, L.
IPC分类号： C07D401/12 , A61K31/4439 , A61K45/06 , C07D471/04
摘要： Provided are compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein Y, CY, R1, R3, R4, R5 R6 R2a R2b, RMa RMb, and the subscripts m, n, and q are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treatment of cancer. Also provided are pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. Also provided are methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

9. 发明申请

WO2021055728A1 SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT 审中-公开
公开(公告)号：WO2021055728A1
公开(公告)日：2021-03-25
申请号：PCT/US2020/051464
申请日：2020-09-18
申请人： MERCK SHARP & DOHME CORP.
发明人： HOOVER, Andrew, J. , GRAHAM, Thomas, H. , MA, Xiaoshen , HUSSAIN, Zahid , MANDAL, Mihir , GATHIAKA, Symon , HAN, Yongxin , SLOMAN, David, L.
IPC分类号： C07D401/12 , A61K31/4439
摘要： Provided are compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein Y, CY, R1, R3, R4, R5 R6 R2a R2b, RMa RMb, and the subscripts m, n, and q are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treatment of cancer. Also provided are pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. Also provided are methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

10. 发明申请

WO2004047365A1 VIRTUAL ROUTER WITH HARDWARE ACCELERATED PACKET MULTICAST 审中-公开
标题翻译：虚拟路由器与硬件加速分组多媒体
公开(公告)号：WO2004047365A1
公开(公告)日：2004-06-03
申请号：PCT/US2003/037009
申请日：2003-11-18
申请人： COSINE COMMUNICATIONS, INC. , CHENG, Joseph , HUSSAIN, Zahid , MILLET, Tim
发明人： CHENG, Joseph , HUSSAIN, Zahid , MILLET, Tim
IPC分类号： H04L12/18
CPC分类号： H04L45/16 , H04L12/18 , H04L12/1886 , H04L45/38 , H04L45/586 , H04L45/60 , H04L45/745 , H04L47/10 , H04L49/201 , H04L69/22 , H04L2012/6489
摘要： A packet-forwarding engine (PFE) of a multiprocessor system uses an array of flow classification block (FCB) indices to multicast a packet. Packets are received and buffered in external memory. In one embodiment, when a multicast packet is identified, a bit is set in a packet descriptor and an FCB index is generated and sent with a null-packet to the egress processors which generate multiple descriptors with different indices for each instance of multicasting. All the descriptors may point to the same buffer in the external memory, which stores the multicast packet. A DMA engine reads from the same buffer multiple times and egress processors may access an appropriate transform control block (TCB) index so that the proper headers may be installed on the outgoing packet. The buffer may be released after the last time the packet is read by setting a particular bit of the FCB index.
摘要翻译：多处理器系统的分组转发引擎（PFE）使用流分类块（FCB）索引的数组来组播数据包。数据包被接收并缓存在外部存储器中。在一个实施例中，当识别出多播分组时，在分组描述符中设置比特，并且生成FCB索引并且向出口处理器发送带有零分组的消息，所述出口处理器为每个多播的实例生成具有不同索引的多个描述符。所有描述符都可以指向存储多播数据包的外部存储器中的相同缓冲区。 DMA引擎从同一缓冲区读取多次，出口处理器可以访问适当的变换控制块（TCB）索引，以便可以在输出数据包上安装合适的报头。通过设置FCB索引的特定位，可以在最后一次读取数据包之后释放缓冲区。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式